Results 21 to 30 of about 5,279 (205)

Evaluating Drug Interaction Risks: Nirmatrelvir & Ritonavir Combination (PAXLOVID^®) with Concomitant Medications in Real-World Clinical Settings

Pathogens
Background: This research article delves into the battle against the COVID-19 pandemic, focusing on the efficacy and, particularly, the safety of the combination of nirmatrelvir with ritonavir, which is found in the pharmaceutical product Paxlovid®. This
Petra Zatovkaňuková, Dalibor Veselý, Jiří Slíva   +2 more
doaj   +2 more sources

Paxlovid in Kidney Failure: A Review [PDF]

MPI (Media Pharmaceutica Indonesiana)
The COVID-19 virus caused a global pandemic that claimed many lives. Various vaccines and drugs are used for COVID-19 both via intravenous and oral routes. Paxlovid is a treatment given orally to patients who experience symptoms and is even considered effective in reducing high-risk COVID-19 virus infections.
Nonie Ardianty, null Suharjono, Didik Hasmono   +2 more
openaire   +2 more sources

Peace, love, Paxlovid and ‘Pfizermectin’

, 2021
As the new Omicron variant of concern of COVID-19 emerged over Thanksgiving week (of all times!), attention has been turning to Paxlovid (PF-07321332). If, like me, you torment yourself by perusing conspiracy theories, you might have heard it referred to as Pfizermectin.
Chris von Csefalvay
openaire   +2 more sources

Clinical outcomes of nirmatrelvir-ritonavir use in pregnant women during the Omicron wave of the coronavirus disease 2019 pandemic

Journal of Infection and Public Health, 2023
Background: Paxlovid is an oral drug composed of nirmatrelvir and ritonavir that has been demonstrated to be effective in decreasing the risk of severe coronavirus disease 2019 (COVID-19).
Chih-Wei Lin, Yu-Ling Liang, Ming-Ta Chuang, Chun-Han Tseng, Pei-Yin Tsai, Mei-Tsz Su   +5 more
doaj   +1 more source

The effectiveness of Paxlovid treatment in long-term care facilities in South Korea during the outbreak of the Omicron variant of SARS-CoV-2 [PDF]

Osong Public Health and Research Perspectives, 2022
Objectives On November 5, 2021, Pfizer Inc. announced Paxlovid (nirmatrelvir+ritonavir) as a treatment method that could reduce the risk of hospitalization or death for patients with confirmed coronavirus disease 2019 (COVID-19). Methods From February 6,
Hanul Park, Young Joon Park, Hye Young Lee, Mi Yu, Yeong-Jun Song, Sang Eun Lee, Ji-Joo Lee, Eun-Sol Lee, Yeonjung Kim   +8 more
doaj   +1 more source

Ranolazine Toxicity Secondary to Paxlovid

Cureus, 2023
An Emergency Use Authorization (EUA) was issued by the FDA on December 22, 2021 for the investigational antiviral drug nirmatrelvir copackaged with the HIV-1 protease inhibitor ritonavir (Paxlovid - Pfizer) for outpatient treatment of mild to moderate COVID-19 in children 12 years and old that are high risk of severe disease.
Casey, Bradley, Vernick, Robert C, Bahekar, Amol, Patel, Divyang, Ncogo Alene, Inmaculada   +4 more
openaire   +2 more sources

Paxlovid accelerates cartilage degeneration and senescence through activating endoplasmic reticulum stress and interfering redox homeostasis

Journal of Translational Medicine, 2022
Background The COVID-19 pandemic has become a huge threat to human health, infecting millions of people worldwide and causing enormous economic losses.
Keyu Kong, Yongyun Chang, Hua Qiao, Chen Zhao, Xuzhuo Chen, Kewei Rong, Pu Zhang, Minghao Jin, Jingwei Zhang, Huiwu Li, Zanjing Zhai   +10 more
doaj   +1 more source

Safety and Efficacy of Paxlovid in COVID-19 Treatment: A Rapid Review

Health Technology Assessment in Action, 2022
Context: In the first stage of viral replication, COVID-19 may cause a remarkable inflammatory response in patients. Paxlovid is an oral antivirus medicine that functions through the inhibition of one of the essential enzymes to viral replication, called
Mohamad Reza Mobinizadeh, Ali Akbarisari, Alireza Olyaeemanesh, Marita Mohammadshahi, Elham Ahmadnezhad, Parisa Aboee, Zahra Gharib Naseri, Zeinab Fakoorfard, Raheleh Sadeghi   +8 more
doaj   +1 more source

Posterior Reversible Encephalopathy Syndrome in an Older Patient in the COVID-19 and Paxlovid Era

Annals of Internal Medicine: Clinical Cases, 2023
Nirmatrelvir/ritonavir (Paxlovid) has been prescribed increasingly for treatment of COVID-19. Due to ritonavir's inhibition of CYP3A4, there are many medication interactions to consider.
Katharine Rosiene, Minisha Lohani, Mario Gemmato-Valecillos, Cristina Marti-Amarista, Sadia Abbasi   +4 more
doaj   +1 more source

Managing nirmatrelvir/ritonavir (Paxlovid) interactions in general practice

, 2023
Nirmatrelvir/ritonavir (Paxlovid) is indicated in patients who are at high risk of progressing to severe COVID-19. Many of these patients are concomitantly prescribed various medications for other indications. Ritonavir has no activity against SARS-CoV-2,
Magdalena Niedzielko, Dagmara Mirowska-Guzel, Rafał Kułakowski   +2 more
core   +1 more source